Global Morphine Market

Morphine Market Size, Share, Growth Analysis, By Type(Injection, Capsules, and Oral Tablets), By Application(Anesthesia, Cough Suppressant, Diarrhea Suppressant, and Others (Cancer), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2204 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 65 | Figures: 75

Morphine Market News

  • In May 2023, Qinhai Zhiyao Pharmaceutical announced the launch of its new morphine sulfate injection in China. The injection is designed to provide rapid pain relief, and it is available in strengths of 10, 20, and 40 milligrams per milliliter.
  • In April 2023, Bard Pharma announced the launch of its new morphine sulfate oral solution in the United States. The solution is designed to be easier to swallow than tablets or capsules, and it is available in strengths of 5, 10, and 20 milligrams per milliliter.
  • In March 2023, Mundipharma announced the launch of its new morphine sulfate extended-release tablets in the United States. The tablets are designed to provide up to 24 hours of pain relief, and they are available in strengths of 15, 30, and 60 milligrams.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Morphine Market size was valued at USD 27.89 Billion in 2022 and is poised to grow from USD 30.03 Billion in 2023 to USD 54.37 Billion by 2031, at a CAGR of 7.7% during the forecast period (2024-2031)

The global morphine market is characterized by the presence of several key players striving to capture a significant market share. These companies engage in various strategies such as mergers and acquisitions, product launches, partnerships, and collaborations to strengthen their market position and expand their product portfolios. collaborations between pharmaceutical companies and healthcare organizations are becoming increasingly common. These collaborations aim to improve patient access to morphine and other pain management solutions, enhance healthcare provider education on responsible opioid use, and develop comprehensive pain management strategies. For example, partnerships between pharmaceutical manufacturers and palliative care organizations focus on improving access to morphine in palliative care settings. In recent years, the competitive landscape has been influenced by the increasing focus on addressing the opioid crisis and promoting responsible opioid use. Companies are actively involved in supporting initiatives aimed at preventing opioid misuse, educating healthcare professionals and patients about the appropriate use of opioids, and developing abuse-deterrent formulations. 'Mallinckrodt Pharmaceuticals (US)', 'Purdue Pharma (US)', 'Johnson Matthey Fine Chemicals (UK)', 'Alcaliber (Spain)', 'Sun Pharmaceutical Industries (India)', 'Janssen Pharmaceuticals (US)', 'Sanofi (France)', 'Teva Pharmaceutical Industries (Israel)', 'Noramco (US)', 'Macfarlan Smith (UK)', 'Tasmanian Alkaloids (Australia)', 'Lannett Company (US)', 'Alkaloid AD Skopje (North Macedonia)', 'Alcaliber SA (Switzerland)', 'Rusan Pharma Ltd (India)', 'Napp Pharmaceuticals (UK)', 'Cipla Ltd (India)', 'Indivior PLC (UK)', 'Purdue Pharma LP (US)', 'Rhodes Pharmaceuticals (US)'

The growing incidence of chronic pain conditions, such as cancer, musculoskeletal disorders, and neuropathic pain, acted as a major driver for the morphine market. In 2022, the World Health Organization estimated that cancer cases would increase by nearly 50% over the next two decades. This rising prevalence of chronic pain conditions has driven the demand for potent analgesics like morphine, contributing to the market's growth.

Focus on Personalized Pain Management: A key trend in the morphine market was the increasing focus on personalized pain management approaches. Healthcare providers and researchers have been exploring individualized treatment strategies based on patient characteristics, genetics, and pain profiles. For instance, in 2022, a study published in the Journal of Pain and Symptom Management discussed the potential of pharmacogenomic testing to optimize opioid therapy, including morphine, by identifying patients at higher risk of adverse events or poor response. This trend signifies the shift towards tailored pain management solutions, which could drive the demand for morphine in specific patient populations.

North America holds the largest market share in the global morphine market due to several factors. The region benefits from well-established healthcare infrastructure, advanced medical facilities, and high healthcare expenditure. Additionally, the region has a high prevalence of chronic pain conditions, including cancer-related pain and musculoskeletal disorders, which necessitate the use of potent analgesics like morphine. Furthermore, favorable government policies, increased awareness about pain management, and the presence of key market players contribute to the dominant position of North America in the morphine market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Morphine Market

Report ID: SQMIG35H2204

$5,300
BUY NOW GET FREE SAMPLE